CSIR launches India’s first ayurvedic anti-diabetic drug named BGR-34
The Council for Scientific and Industrial Research (CSIR) has launched the country’s first anti-diabetic ayurvedic drug named BGR-34 for type two Diabetes mellitus.
BGR-34 stands for Blood Glucost Regulator and offers effective, safe, patient-friendly solution for managing type two Diabetes.
- The drug has been jointly developed by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP) and CSIR institutes based in Lucknow.
- It contains 34 identified active phyto-constitutes from herbal resources and works by controlling blood sugar and limiting the harmful effects of other modern drugs.
- For the purpose of quality commercial production and extended distribution of this drug, CSIR has transferred the rights and technical details to AIMIL Pharmaceuticals (I) Ltds.